
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is poised to benefit from its robust therapeutic portfolio, led by Keytruda in immuno-oncology and Gardasil in vaccines. With the acquisition of Terns, Merck has solidified its position in the competitive landscape for treatment options in liver diseases and has potential blockbuster drugs in its pipeline with advancements in Terns `s therapy. The company's successful execution of its growth strategy along with a strong financial position and a steady dividend history, make it a long-term investment opportunity for investors seeking stable returns.
Bears say
Merck & Co is facing several challenges as the company approaches its second quarter earnings. Key factors shaping the quarter include moderate growth of Keytruda in the US and ongoing pricing headwinds in international markets, along with expected pressure on sales of Januvia/Janumet due to IRA pricing and increased competition. However, the company's pipeline and upcoming catalysts, such as full data releases for Islatravir + Lenacapavir and potential FDA approval for enlicitide, suggest potential for growth. Additionally, the company's diverse portfolio, global presence, and continued investment in pipeline development may mitigate these challenges and position Merck for long-term success.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares